Kite Pharma, Roche to co-develop two new treatments for non-hodgkin lymphoma
pharmafile | March 18, 2016 | News story | Medical Communications, Research and Development | Gentech, Roche, kite pharma, non-Hodgkin lymphoma
Kite Pharma (Nasdaq: KITE) said it will collaborate with Swiss drug major Roche (SIX: ROG) to evaluate the safety and efficacy of its drug compound in combination with KTE-C19, in combination with atezolizumab to treat non-Hodgkin lymphoma (NHL).
The company said it expects to start multi-center Phase I/ II study with Genentech, a unit of Roche, in 2016.
Arie Belldegrun, chief executive of Kite, says: “Kite is a pioneer in engineered T cell therapy, and we are excited to collaborate with Genentech, an industry leader with a history of developing transformative therapies for cancer. KTE-C19 is currently in four pivotal studies and early clinical findings have shown a potential for breakthrough efficacy in refractory, aggressive NHL and other B cell malignancies. The scientific rationale for combining KTE-C19 and atezolizumab in refractory, aggressive NHL is compelling, and could potentially lead to opportunities to advance this combination in other indications.”
KTE-C19 is an investigational immunotherapy in which a patient’s T cells are genetically modified to express a CAR designed to target the antigen CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. Atezolizumab is an investigational monoclonal antibody designed to target and bind to a protein called PD-L1, which is expressed on tumor cells and tumor-infiltrating immune cells.
Anjali Shukla
Related Content

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …

Roche advances treatment for Parkinson’s disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …






